company background image
IMNN

Imunon NasdaqCM:IMNN Stock Report

Last Price

US$1.60

Market Cap

US$11.9m

7D

2.6%

1Y

-74.8%

Updated

04 Feb, 2023

Data

Company Financials +

IMNN Stock Overview

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies.

IMNN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

My Notes

New

Notes are coming soon

Imunon, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Imunon
Historical stock prices
Current Share PriceUS$1.60
52 Week HighUS$7.68
52 Week LowUS$1.26
Beta2.05
1 Month Change-0.62%
3 Month Change3.23%
1 Year Change-74.81%
3 Year Change-92.33%
5 Year Change-94.97%
Change since IPO-99.99%

Recent News & Updates

Celsion changes name to Imunon (IMNN)

Sep 19

Recent updates

Celsion changes name to Imunon (IMNN)

Sep 19

Celsion says additional data shows placcine vaccine works against COVID-19 in animal model

Sep 01

Celsion Q2 2022 Earnings Preview

Aug 12

Celsion adds Moderna chief commercial officer as CEO

Jul 19

Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?

Dec 07
Is Celsion (NASDAQ:CLSN) Using Debt Sensibly?

Is Celsion (NASDAQ:CLSN) Using Too Much Debt?

Aug 18
Is Celsion (NASDAQ:CLSN) Using Too Much Debt?

What We Learned About Celsion's (NASDAQ:CLSN) CEO Compensation

Dec 01
What We Learned About Celsion's (NASDAQ:CLSN) CEO Compensation

Celsion slips 4% on Q3 earnings miss

Nov 16

Shareholder Returns

IMNNUS BiotechsUS Market
7D2.6%-0.8%1.7%
1Y-74.8%4.4%-9.6%

Return vs Industry: IMNN underperformed the US Biotechs industry which returned 4.5% over the past year.

Return vs Market: IMNN underperformed the US Market which returned -8.5% over the past year.

Price Volatility

Is IMNN's price volatile compared to industry and market?
IMNN volatility
IMNN Average Weekly Movement7.8%
Biotechs Industry Average Movement12.1%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: IMNN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 8% a week.

Volatility Over Time: IMNN's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198229Corinne Le Goffhttps://www.imunon.com

Imunon, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies.

Imunon, Inc. Fundamentals Summary

How do Imunon's earnings and revenue compare to its market cap?
IMNN fundamental statistics
Market CapUS$11.89m
Earnings (TTM)-US$26.89m
Revenue (TTM)US$500.00k

23.8x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMNN income statement (TTM)
RevenueUS$500.00k
Cost of RevenueUS$11.72m
Gross Profit-US$11.22m
Other ExpensesUS$15.67m
Earnings-US$26.89m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-3.62
Gross Margin-2,243.33%
Net Profit Margin-5,377.37%
Debt/Equity Ratio14.5%

How did IMNN perform over the long term?

See historical performance and comparison